Collegium Pharmaceutical (COLL) Non-Current Deffered Revenue (2024 - 2026)

Collegium Pharmaceutical has reported Non-Current Deffered Revenue for 3 years, with the latest figure at $8.8 million in Q2 2026.

• On a quarterly basis, Non-Current Deffered Revenue fell 12.22% year-over-year to $8.8 million in Q2 2026; TTM through Jun 2026 was $8.8 million, a 12.22% decrease from a year earlier, with the FY2025 full-year figure at $9.1 million, down 8.89% from the prior year.
• Non-Current Deffered Revenue was $8.8 million for Q2 2026 at Collegium Pharmaceutical, down from $8.9 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $10.0 million in Q3 2024, with the low at $8.8 million in Q2 2026.
• Average Non-Current Deffered Revenue over 3 years is $9.5 million, with a median of $9.6 million recorded in 2024.
• The sharpest annual moves came in 2025 and 2026: Non-Current Deffered Revenue decreased 7.22% in 2025, then retreated 12.22% in 2026.
• Over 3 years, Non-Current Deffered Revenue stood at $10.0 million in 2024, then retreated by 8.89% to $9.1 million in 2025, then dropped by 3.65% to $8.8 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $8.8 million (Q2 2026), $8.9 million (Q1 2026), and $9.1 million (Q4 2025), per Business Quant data.